Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
| Autor: | Hans-Juergen Woerle, Uli C. Broedl, V. Seshiah, Russell Jones, R. Swallow, Henning Rattunde, Christopher S. Kovacs |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism Urology Placebo-controlled study Type 2 diabetes Placebo Endocrinology Double-Blind Method Glucosides Sodium-Glucose Transporter 2 Weight Loss Internal Medicine Empagliflozin medicine Humans Hypoglycemic Agents Benzhydryl Compounds Adverse effect Sodium-Glucose Transporter 2 Inhibitors Aged Pioglitazone business.industry Body Weight nutritional and metabolic diseases Middle Aged medicine.disease Metformin Treatment Outcome Tolerability Diabetes Mellitus Type 2 Drug Therapy Combination Female Thiazolidinediones business medicine.drug |
| Zdroj: | Diabetes, obesitymetabolism. 16(2) |
| ISSN: | 1463-1326 |
| Popis: | Aims This study investigated the efficacy and tolerability of empagliflozin as add-on to pioglitazone ± metformin in patients with type 2 diabetes (T2DM). Methods Patients with HbA1c ≥7 and ≤10% were randomized and treated with once daily empagliflozin 10 mg (n = 165), empagliflozin 25 mg (n = 168) or placebo (n = 165) as add-on to pioglitazone ± metformin for 24 weeks. Endpoints included changes from baseline in HbA1c (primary endpoint), fasting plasma glucose (FPG) and body weight at week 24. Results Adjusted mean ± standard error changes in HbA1c were −0.6 ± 0.07% and −0.7 ± 0.07% with empagliflozin 10 mg and 25 mg, respectively, vs. −0.1 ± 0.07% with placebo (both p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text